Inhalation Device Platforms

Inhalation Device Platforms
Product Description

Access the delivery technology best suited to the needs of your development programme, including unit-dose and multi-unit dose DPIs, pMDIs and smart nebulisers, suitable for home or hospital applications.

Dry Powder Inhalers:
Options include proprietary unit- and multi-unit dose platforms, as well as off-the-shelf capsule devices, to support your programme from early development through to a commercial-ready device.

Nebulisers:
Our state-of-the-art breath-actuated nebulisers with guided inhalation have been developed to improve lung delivery for inhaled drugs, with the aim of achieving better clinical outcomes and/or shortened treatment times.

Metered Dose Inhalers:
With extensive expertise in pMDI development and lifecycle management, we can help develop a new pMDI product or optimise your existing formulation and device performance. 

Read more Show less

VECTURA GROUP PLC

  • GB
  • 2020
    On CPHI since
  • 250 - 499
    Employees
Company types
Contract Service
View company profile
Categories
more categories Show less

VECTURA GROUP PLC

  • GB
  • 2020
    On CPHI since
  • 250 - 499
    Employees
Company types
Contract Service
View company profile

More Products from VECTURA GROUP PLC (4)

  • Inhaled Formulation Development

    Product Inhaled Formulation Development

    With expertise in powder and liquid formulations for small molecules and biologics, as well as a broad portfolio of proprietary device and formulation technologies, we can help you overcome the challenges of inhaled formulation development.

    Dry Powder Formulation
    Advanced po...
  • Analytical Services - Inhaled Products

    Product Analytical Services - Inhaled Products

    With extensive, state-of-the-art analytical testing facilities and equipment, our expert teams are able to develop and validate the methodologies required to characterise inhaled delivery platforms, especially DPI, pMDI and nebulised products.

    To ensure seamless support for your development...
  • Process Development & Inhaled Product Manufacturing

    Product Process Development & Inhaled Product Manufacturing

    In addition to extensive development manufacturing facilities, Vectura has GMP manufacturing facilities for dry powder inhalers, pMDI and nebuliser medical devices as well as further capability to handle biological molecules. 

    Our GMP manufacturing facilities and equipment are relevant-to-comme...
  • Medical & Regulatory Services - Inhaled Products

    Product Medical & Regulatory Services - Inhaled Products

    Our formulation, device and development services are supported by our medical, regulatory, device vigilance and pharmacovigilance teams to safeguard your programme and ensure the smoothest path to product approval.

    Our in-house team can support with:

    Global regulatory development strategy...

VECTURA GROUP PLC resources (2)

  • Discover the CPHI North America Learning Labs: Part Two

    News Discover the CPHI North America Learning Labs: Part Two

    Explore the series of Learning Labs at CPHI North America in which thought leaders at our exhibitors showcase their extensive knowledge on all areas of the pharma supply chain, offering industry insights across drug manufacturing, outsourcing, pharma ingredients, drug delivery and packaging.
    2 Aug 2021
  • Take a Breath: Selecting a Device for Inhaled Product Development

    Video Take a Breath: Selecting a Device for Inhaled Product Development

    This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. The future commercial success of any new inhaled medicine relies largely on the correct combination of formulation and device technology chosen for its delivery. This presentation benefits any drug developer considering an inhaled programme and aims to answer the following questions: How are development targets and success criteria set for inhaled products? What are the key factors influencing inhaled delivery platform selection? How can phase-appropriate device selection accelerate an inhaled development programme?
    2021-11-23